Investigation of antitumor activities of trastuzumab delivered by PLGA nanoparticles

References

• ScottAMWolchokJDOldLJAntibody therapy of cancerNat Rev Cancer201212427828722437872
   PubMed Web of Science ®Google Scholar
• GotwalsPCameronSCipollettaDProspects for combining targeted and conventional cancer therapy with immunotherapyNat Rev Cancer201717528630128338065
   PubMed Web of Science ®Google Scholar
• ZumlaARaoMWallisRSHost-Directed Therapies Network consortiumHost-directed therapies for infectious diseases: current status, recent progress, and future prospectsLancet Infect Dis2016164e47e6327036359
   PubMed Web of Science ®Google Scholar
• EckerDMJonesSDLevineHLThe therapeutic monoclonal antibody marketMAbs20157191425529996
   PubMed Web of Science ®Google Scholar
• HudisCATrastuzumab – mechanism of action and use in clinical practiceN Engl J Med20073571395117611206
   PubMed Web of Science ®Google Scholar
• BriaECupponeFDi MaioMCetuximab for metastatic colorectal cancerN Engl J Med200936119596
   PubMedGoogle Scholar
• SawyersCTargeted cancer therapyNature2004432701529429715549090
   PubMed Web of Science ®Google Scholar
• HuangACPostowMAOrlowskiRJT-cell invigoration to tumour burden ratio associated with anti-PD-1 responseNature20175457652606528397821
   PubMed Web of Science ®Google Scholar
• WeinerLMSuranaRWangSMonoclonal antibodies: versatile platforms for cancer immunotherapyNat Rev Immunol201010531732720414205
   PubMed Web of Science ®Google Scholar
• ChildsRWCarlstenMTherapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakensNat Rev Drug Discov201514748749826000725
   PubMed Web of Science ®Google Scholar
• Gras NavarroABjörklundATChekenyaMTherapeutic potential and challenges of natural killer cells in treatment of solid tumorsFront Immunol2015620225972872
   PubMed Web of Science ®Google Scholar
• HanselTTKropshoferHSingerTMitchellJAGeorgeAJThe safety and side effects of monoclonal antibodiesNat Rev Drug Discov20109432533820305665
   PubMed Web of Science ®Google Scholar
• BöttgerRHoffmannRKnappeDDifferential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serumPLoS One2017126e017894328575099
   PubMed Web of Science ®Google Scholar
• MittapalliRKAdkinsCEBohnKAMohammadASLockmanJALockmanPRQuantitative fluorescence microscopy measures vascular pore size in primary and metastatic brain tumorsCancer Res201777223824627815391
   PubMed Web of Science ®Google Scholar
• SousaFCastroPFontePKennedyPJNeves-PetersenMTSarmentoBNanoparticles for the delivery of therapeutic antibodies: dogma or promising strategy?Expert Opin Drug Deliv201629114
   Google Scholar
• VarshochianRRiazi-EsfahaniMJeddi-TehraniMAlbuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatmentJ Biomed Mater Res A2015103103148315625773970
   PubMed Web of Science ®Google Scholar
• LiFHurleyBLiuYLeonardBGriffithMControlled release of bevacizumab through nanospheres for extended treatment of age-related macular degenerationOpen Ophthalmol J20126545822798970
   PubMedGoogle Scholar
• DanhierFAnsorenaESilvaJMCocoRLe BretonAPréatVPLGA-based nanoparticles: an overview of biomedical applicationsJ Control Release2012161250552222353619
   PubMed Web of Science ®Google Scholar
• KamalyNYameenBWuJFarokhzadOCDegradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug releaseChem Rev201611642602266326854975
   PubMed Web of Science ®Google Scholar
• KhangGRheeJMJeongJKLocal drug delivery system using biodegradable polymersMacromol Res2003114207223
   Web of Science ®Google Scholar
• ManishMRahiAKaurMBhatnagarRSinghSA single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against Bacillus anthracis spore challengePLoS One201384e6188523637922
   PubMed Web of Science ®Google Scholar
• FornagueraCDols-PerezACalderóGGarcía-CelmaMJCamarasaJSolansCPLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrierJ Control Release201521113414326057857
   PubMed Web of Science ®Google Scholar
• JainAKSwarnakarNKDasMAugmented anticancer efficacy of doxorubicin-loaded polymeric nanoparticles after oral administration in a breast cancer induced animal modelMol Pharm2011841140115121557558
   PubMed Web of Science ®Google Scholar
• JainAKSwarnakarNKGoduguCSinghRPJainSThe effect of the oral administration of polymeric nanoparticles on the efficacy and toxicity of tamoxifenBiomaterials201132250351520934747
   PubMed Web of Science ®Google Scholar
• LiuHSlamovichEBWebsterTJLess harmful acidic degradation of poly(lactic-co-glycolic acid) bone tissue engineering scaffolds through titania nanoparticle additionInt J Nanomedicine20061454154517722285
   PubMed Web of Science ®Google Scholar
• SousaFCruzAFontePPintoIMNeves-PetersenMTSarmentoBA new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticlesSci Rep201771373628623267
   PubMedGoogle Scholar
• SánchezATobíoMGonzálezLFabraAAlonsoMJBiodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alphaEur J Pharm Sci2003183–422122912659933
   PubMed Web of Science ®Google Scholar
• Carrillo-CondeBRDarlingRJSeilerSJRamer-TaitAEWannemuehlerMJNarasimhanBSustained release and stabilization of therapeutic antibodies using amphiphilic polyanhydride nanoparticlesChem Eng Sci201512598107
   Web of Science ®Google Scholar
• GreenfieldNJUsing circular dichroism spectra to estimate protein secondary structureNat Protoc2006162876289017406547
   PubMed Web of Science ®Google Scholar
• MicsonaiAWienFKernyaLAccurate secondary structure prediction and fold recognition for circular dichroism spectroscopyProc Natl Acad Sci U S A201511224E3095E310326038575
   PubMed Web of Science ®Google Scholar
• GoormaghtighERaussensVRuysschaertJMAttenuated total reflection infrared spectroscopy of proteins and lipids in biological membranesBiochim Biophys Acta19991422210518510393271
   PubMed Web of Science ®Google Scholar
• DetermanASWilsonJHKipperMJWannemuehlerMJNarasimhanBProtein stability in the presence of polymer degradation products: consequences for controlled release formulationsBiomaterials200627173312332016504288
   PubMed Web of Science ®Google Scholar
• FontePSoaresSSousaFStability study perspective of the effect of freeze-drying, using cryoprotectants on the structure of insulin Loaded into PLGA nanoparticlesBiomacromolecules201415103753376525180545
   PubMed Web of Science ®Google Scholar
• SainzVPeresCCimanTOptimization of protein loaded PLGA nanoparticle manufacturing parameters following a quality-by-design approachRSC Adv20166106104502104512
   Web of Science ®Google Scholar
• OcchipintiEVerderioPNatalelloAInvestigating the structural biofunctionality of antibodies conjugated to magnetic nanoparticlesNanoscale20113238739020877896
   PubMed Web of Science ®Google Scholar
• GinestierCAdélaïdeJGonçalvèsAERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell linesOncogene200726507163716917525746
   PubMed Web of Science ®Google Scholar
• ColomboMCorsiFFoschiDHER2 targeting as a two-sided strategy for breast cancer diagnosis and treatment: outlook and recent implications in nanomedical approachesPharmacol Res201062215016520117211
   PubMed Web of Science ®Google Scholar
• AustinCDDe MazièreAMPisacanePIEndocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycinMol Biol Cell200415125268528215385631
   PubMed Web of Science ®Google Scholar
• NagataYLanKHZhouXPTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patientsCancer Cell20046211712715324695
   PubMed Web of Science ®Google Scholar
• ColomboMFiandraLAlessioGTumour homing and therapeutic effect of colloidal nanoparticles depend on the number of attached antibodiesNat Commun201671381827991503
   PubMed Web of Science ®Google Scholar
• CorsiFFiandraLDe PalmaCHER2 expression in breast cancer cells is downregulated upon active targeting by antibody-engineered multifunctional nanoparticles in miceACS Nano2011586383639321790185
   PubMed Web of Science ®Google Scholar
• DokmanovicMWuYShenYChenJHirschDSWuWJTrastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibitionCancer Biol Ther20141581029104124835103
   PubMed Web of Science ®Google Scholar
• DokmanovicMWuWJTrastuzumab-induced HER2 phosphorylation: exploring the mechanisms and implicationsReceptor Clin Invest201414e340
   Google Scholar
• EspelinCWLeonardSCGerettiEWickhamTJHendriksBSDual HER2 targeting with trastuzumab and liposomal-encapsulated doxorubicin (MM-302) demonstrates synergistic antitumor activity in breast and gastric cancerCancer Res20167661517152726759238
   PubMed Web of Science ®Google Scholar
• CollinsDMO’DonovanNMcGowanPMO’SullivanFDuffyMJCrownJTrastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell linesAnn Oncol20122371788179522056974
   PubMed Web of Science ®Google Scholar
• GuillereyCHuntingtonNDSmythMJTargeting natural killer cells in cancer immunotherapyNat Immunol20161791025103627540992
   PubMed Web of Science ®Google Scholar